NCT01990846View on ClinicalTrials.gov

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Influenza
Interventions
DRUG

Flufirvitide 3

DRUG

Placebo for Flufirvitide-3

Trial Locations (1)

29303

Spartanburg Medical Research, Spartanburg

Sponsors
All Listed Sponsors
lead

Autoimmune Technologies, LLC

INDUSTRY

NCT01990846 - Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects | Biotech Hunter | Biotech Hunter